ViroPharma Inc. (VPHM) announced Tuesday morning that the FDA denied the citizen petition filed by ViroPharma on March 17, 2006, related to the FDA's proposed in vitro method for determining bioequivalence of abbreviated new drug applications referencing Vancocin Capsules.
ViroPharma has gapped open sharply lower Tuesday and is now down 5.07 at $23.54 on strong volume. The stock has dropped to a 4-month low and has fallen below its 200-day moving average.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org